NasdaqGM:BCAXBiotechs
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug
Bicara Therapeutics recently completed a follow-on equity offering of about US$150.00 million in common stock and pre-funded warrants to support late-stage development and potential commercialization of its lead cancer therapy, ficerafusp alfa.
This financing follows encouraging Phase 1b data and Breakthrough Therapy Designation for ficerafusp alfa in head and neck cancer, underscoring how Bicara is positioning itself for future regulatory milestones and commercialization efforts.
Next,...